PerkinElmer, Inc. (NYSE:PKI)‘s stock had its “buy” rating reissued by equities research analysts at Robert W. Baird in a research note issued on Friday. They currently have a $72.00 price objective on the medical research company’s stock. Robert W. Baird’s price objective indicates a potential upside of 0.38% from the stock’s previous close.

A number of other brokerages have also weighed in on PKI. BidaskClub lowered PerkinElmer from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Evercore ISI restated an “in-line” rating and issued a $68.00 price objective (up previously from $62.50) on shares of PerkinElmer in a report on Thursday, June 22nd. Piper Jaffray Companies restated a “buy” rating and issued a $81.00 price objective on shares of PerkinElmer in a report on Friday, August 4th. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 price objective on the stock in a report on Tuesday, August 1st. Finally, Citigroup Inc. raised their price objective on PerkinElmer from $67.00 to $74.00 and gave the company a “buy” rating in a report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $68.14.

PerkinElmer (NYSE PKI) traded up 0.57% during trading on Friday, hitting $71.73. 462,010 shares of the stock traded hands. The stock has a 50 day moving average price of $69.39 and a 200-day moving average price of $65.31. The stock has a market cap of $7.91 billion, a P/E ratio of 21.63 and a beta of 0.72. PerkinElmer has a 52-week low of $45.35 and a 52-week high of $72.11.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The company had revenue of $547.00 million for the quarter, compared to analyst estimates of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The firm’s revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. On average, analysts anticipate that PerkinElmer will post $2.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “PerkinElmer’s (PKI) Buy Rating Reaffirmed at Robert W. Baird” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/21/perkinelmers-pki-buy-rating-reaffirmed-at-robert-w-baird.html.

Several institutional investors and hedge funds have recently modified their holdings of PKI. Waldron LP acquired a new stake in shares of PerkinElmer in the 1st quarter worth $233,000. Russell Investments Group Ltd. increased its stake in shares of PerkinElmer by 13.4% in the 1st quarter. Russell Investments Group Ltd. now owns 21,459 shares of the medical research company’s stock worth $1,245,000 after acquiring an additional 2,531 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of PerkinElmer by 15.0% in the 1st quarter. UBS Asset Management Americas Inc. now owns 73,057 shares of the medical research company’s stock worth $4,242,000 after acquiring an additional 9,507 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of PerkinElmer by 28.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock worth $115,000 after acquiring an additional 434 shares during the last quarter. Finally, United Services Automobile Association increased its stake in shares of PerkinElmer by 0.9% in the 1st quarter. United Services Automobile Association now owns 34,183 shares of the medical research company’s stock worth $1,985,000 after acquiring an additional 296 shares during the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.